May 15, 2024Leukemia & lymphoma/Leukemia and lymphoma
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia
Authors
Discussion
Loading...
Member takes
Implication
Phase 2 trial demonstrates durable remissions and high survival with sequential cladribine and rituximab in hairy cell leukemia, highlighting sustained frontline and relapse efficacy.
Key Points
- Treatment with sequential cladribine and rituximab induces durable complete responses with high rates of measurable residual disease clearance in hairy cell leukemia.
- Complete response occurred in 97% of evaluable patients, and 102 individuals achieved measurable residual disease negativity during extended clinical follow-up.
- Phase 2 trial evaluation demonstrates manageable toxicity and durable event-free survival, supporting the sequential combination in frontline and relapsed settings.
Cite This Study
Marvin‐Peek et al. (2024) studied this question.